pyrazines has been researched along with Cystadenocarcinoma, Serous in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| D'Andrea, AD; Do, KT; Dunn, CE; Färkkilä, A; Kirschmeier, PT; Kochupurakkal, BS; Konstantinopoulos, PA; Lazaro, JB; Liu, JF; Matulonis, UA; Palakurthi, S; Parmar, K; Reavis, HD; Reznichenko, E; Sambel, LA; Shapiro, GI; Wang, ZC; Yang, C; Zou, L | 1 |
| Li, R; Liu, P; Liu, T; Luan, W; Mao, H; Shi, J; Wei, X; Yu, J | 1 |
| Barra, F; Costantini, S; Evangelisti, G; Ferrero, S; Gustavino, C; Moioli, M; Sala, P; Stigliani, S | 1 |
| Haynes, B; Huang, TT; Lee, JM; Murai, J; Nair, J; Pommier, Y; Steeg, PS | 1 |
| An, D; Cimino-Mathews, A; Lampert, EJ; Lee, JM; Lee, JS; Lee, MJ; Nair, J; Ruppin, E; Trepel, JB; Yuno, A | 1 |
| de Jonge, A; Do, KT; Giobbie-Hurder, A; Hu, J; Kelland, S; Manuszak, C; Powers, A; Severgnini, M; Shapiro, GI; Thrash, E | 1 |
| D'Andrea, AD; de Jonge, A; Do, KT; Gannon, C; Hedglin, J; Kelland, S; Kochupurakkal, B; Lazaro, JB; Parmar, K; Powers, A; Quinn, N; Shapiro, GI; Vuong, L | 1 |
| Annunziata, CM; Bagheri, MH; Botesteanu, DA; Ekwede, I; Harrell, MI; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Merino, MJ; Minasian, L; Nair, J; Steinberg, SM; Swisher, EM; Trepel, JB; Zimmer, A | 1 |
| Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
| Fernández, FM; Gaul, DA; Huang, D; Kim, J; Nan, H | 1 |
| Deavers, MT; Gershenson, DM; King, ER; Malpica, A; Mok, SC; Tsang, YT; Wong, KK; Zu, Z | 1 |
| Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
1 review(s) available for pyrazines and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Drug Synergism; Female; Humans; Neoplasm Grading; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2020 |
3 trial(s) available for pyrazines and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Clinical outcomes of prexasertib monotherapy in recurrent
Topics: Aged; Cystadenocarcinoma, Serous; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Pyrazines; Pyrazoles; Tumor Microenvironment | 2020 |
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2021 |
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
8 other study(ies) available for pyrazines and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Neoplasm Grading; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2019 |
ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Down-Regulation; Endoplasmic Reticulum Stress; Endoribonucleases; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Imidazoles; MAP Kinase Signaling System; Middle Aged; Naphthalenes; Neoplasm Grading; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Receptor Tyrosine Kinase-like Orphan Receptors; Transcription Factor CHOP; Tumor Stem Cell Assay | 2019 |
Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
Topics: BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Pyrazines; Pyrazoles | 2020 |
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Ovarian Neoplasms; Pyrazines; Pyrazoles | 2021 |
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome; United States; Young Adult | 2018 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
Topics: Animals; Bilirubin; Biomarkers, Tumor; Chromatography, Liquid; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Humans; Metabolomics; Mice; Mice, Knockout; Neoplasm Staging; Oligopeptides; Ovarian Neoplasms; Phospholipids; Pyrazines; Sphingomyelins; Sterols; Tandem Mass Spectrometry; Uridine | 2019 |
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
Topics: Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Insulin-Like Growth Factor I; Molecular Targeted Therapy; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Signal Transduction; Up-Regulation | 2011 |